TG Therapeutics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.44 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 4.8× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| TGTX | TTWO | |
|---|---|---|
Market Cap | $8.16B | $39.15B |
Volume | 1,735,121 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $59.06 | $262.29 |
52-Week Low | $26.94 | $189.69 |
Typical Hold Time | 16 Days | 111 Days |
Enterprise Value | $8.37B | $40.27B |
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Take-Two Interactive (TTWO) trades at $213.44, up 4.62% today, showing strong momentum ahead of GTA VI's November launch. The stock maintains a bullish technical signal with support at $206 and resistance at $215. Despite recent earnings volatility with a Q2 miss, analyst consensus remains overwhelmingly positive with 79% buy ratings and a $292.30 price target, representing 37% upside potential from current levels.
While TTWO faces fundamental challenges with negative net margins and elevated debt levels, the imminent GTA VI release provides significant catalyst potential. Investors should weigh the substantial growth opportunity against execution risks and current valuation metrics that price in successful game performance. The stock's trajectory will likely hinge on GTA VI's commercial success and the company's ability to return to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →